Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Carcinoma, Non-Small-Cell Lung 126Lung Neoplasms 51Triple Negative Breast Neoplasms 35Breast Neoplasms 34Small Cell Lung Carcinoma 30Ovarian Neoplasms 27Squamous Cell Carcinoma of Head and Neck 25Neoplasm Metastasis 21Fallopian Tube Neoplasms 20Endometrial Neoplasms 19Neoplasms 17Parkinson Disease 4, Autosomal Dominant Lewy Body 14Head and Neck Neoplasms 13Colorectal Neoplasms 11Carcinoma 11Prostatic Neoplasms 9Oropharyngeal Neoplasms 9Esophageal Neoplasms 9Urinary Bladder Neoplasms 8Carcinoma, Transitional Cell 8Pancreatic Neoplasms 7Carcinoma, Squamous Cell 7Lung Diseases 6Laryngeal Neoplasms 6Carcinoma, Ovarian Epithelial 6Adenocarcinoma of Lung 6Uterine Cervical Neoplasms 5Respiratory Tract Neoplasms 5Mouth Neoplasms 5Mesothelioma 5

Interventions

Cisplatin 18Gemcitabine 14Radiotherapy, Intensity-Modulated 11Magnetic Resonance Spectroscopy 8toripalimab 7Specimen Handling 7Capecitabine 7Platinum 5Drug Therapy 51,2-diaminocyclohexaneplatinum II citrate 5camrelizumab 4Radiotherapy 4Nivolumab 4spartalizumab 3sintilimab 3anlotinib 3Immunoglobulin G 3Immune Checkpoint Inhibitors 3Docetaxel 3Disulfides 3atezolizumab 2Radiation 2Phantoms, Imaging 2Ipilimumab 2Carboplatin 2CTLA-4 Antigen 2Biopsy 2Bevacizumab 218-O-demethylcervinomycin A2 2tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × Carboplatin × 90 days × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06029270 2026-06-03

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
156 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡